Publication
Advanced ovarian cancer: what should be the standard of care?
Authors not recorded
- Source
- PubMed
- Retrieved
- Sep 8, 2026
- Layer
- normalized (units and labels harmonized; values unchanged)
- Run
- ING-CIVIC-20260908-000001
Abstract
Abstract (excerpt)
Only the opening of the abstract is shown; abstract text may carry publisher copyright.
Data not yet available
Linked entities
Linked entities (6)
How each link was made (MeSH, dictionary, registry reference, curation…) and whether it has been validated. Candidate links are not counted in entity statistics.
Validated 6
- cancerMalignant Ovarian Neoplasmcivic_curation1.00
- drugOlaparibcivic_curation1.00
- geneBRCA1civic_curation1.00
- geneBRCA2civic_curation1.00
- variantBRCA1 Loss-of-functioncivic_curation1.00
- variantBRCA2 Loss-of-functioncivic_curation1.00
Curated evidence
Evidence citing this paper (2)
- Source
- CIViC — Clinical Interpretation of Variants in Cancer
- Dataset
- CIViC evidence items
- Version
- civic-2026-09-08
- Retrieved
- Sep 8, 2026
- Layer
- normalized (units and labels harmonized; values unchanged)
- Evidence
- expert curation
- License
- CC0 1.0
- PMID
- 23346317
- Run
- ING-CIVIC-20260908-000001
| Therapy | Cancer | Type | Level | Direction · significance | Rating (1–5) | Status | Evidence | Source |
|---|---|---|---|---|---|---|---|---|
| BRCA1 Loss-of-function1 | ||||||||
| Olaparib | Malignant Ovarian Neoplasm | Predictive | B | Supports Sensitivity Response | 4 | accepted | EID211The combination of PARP inhibition (Olaparib) with BRCA mutation results in irreparable and lethal DNA damage. Response rates are higher in BRCA1 mutation positive women with high grade serous or undi… (full text at CIViC) PMID 23346317 · Goff, 2013 · Open in CIViC | civic |
| BRCA2 Loss-of-function1 | ||||||||
| Olaparib | Malignant Ovarian Neoplasm | Predictive | B | Supports Sensitivity Response | 4 | accepted | EID212The combination of PARP inhibition (Olaparib) with BRCA mutation results in irreparable and lethal DNA damage. Response rates are higher in BRCA2 mutation positive women with high grade serous or undi… (full text at CIViC) PMID 23346317 · Goff, 2013 · Open in CIViC | civic |